"Geneos' Personalized Cancer Vaccine Shrinks Liver Tumors in Positive Trial Results"
In a small trial, a personalized cancer vaccine developed by Geneos Therapeutics, combined with an immunotherapy drug, shrank liver tumors in nearly a third of patients with advanced liver cancer. The vaccine, based on mutations specific to each patient's tumor, aims to boost the immune system's ability to recognize and attack hard-to-treat cancers. The promising results suggest a step forward in effective cancer vaccines and may expand the types of cancers that such therapies can treat. Larger trials are being planned to confirm these findings.
